Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors

BMC Genomics

Volumn 12, Issue , 2011, Pages

  Kryh, Hanna ^a   Carén, Helena ^a   Erichsen, Jennie ^a   Sjöberg, Rose Marie ^a   Abrahamsson, Jonas ^a   Kogner, Per ^b   Martinsson, Tommy ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ALLELIC IMBALANCE; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL STRAIN SH EP; CELL STRAIN SH SY5Y; CELL STRAIN SK N SH; CHROMOSOME NUMBER; CONTROLLED STUDY; COPY NEUTRAL LOSS OF HETEROZYGOSITY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; NEUROBLASTOMA CELL; SINGLE NUCLEOTIDE POLYMORPHISM; COMPARATIVE STUDY; DNA MICROARRAY; GENE DOSAGE; GENETICS; METHODOLOGY; NEUROBLASTOMA; PLOIDY; TUMOR CELL LINE;

ALLELIC IMBALANCE; CELL LINE, TUMOR; GENE DOSAGE; HUMANS; LOSS OF HETEROZYGOSITY; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLOIDIES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80052563044     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-12-443     Document Type: Article

References (29)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216. 10.1038/nrc1014, 12612655.
2. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033. 10.1200/JCO.2008.16.0630, 19171713.
3. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, Abrahamsson J, Kogner P, Martinsson T. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors; Four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 2008, 9:353. 10.1186/1471-2164-9-353, 2527340, 18664255.
4. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 2010, 107:4323-4328. 10.1073/pnas.0910684107, 2840092, 20145112.
5. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 2007, 46:1098-1108. 10.1002/gcc.20496, 17823929.
6. Hiyama E, Yamaoka H, Kamimatsuse A, Onitake Y, Hiyama K, Nishiyama M, Sueda T. Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients. J Pediatr Surg 2006, 41:2032-2036. 10.1016/j.jpedsurg.2006.08.002, 17161199.
7. Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 2007, 177:20-29. 10.1016/j.cancergencyto.2007.05.002, 17693187.
8. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006, 45:1130-1142. 10.1002/gcc.20376, 16958102.
9. Chen QR, Bilke S, Khan J. High-resolution cDNA microarray-based comparative genomic hybridization analysis in neuroblastoma. Cancer Lett 2005, 228:71-81. 10.1016/j.canlet.2004.12.056, 15951107.
10. De Preter K, Pattyn F, Berx G, Strumane K, Menten B, Van Roy F, De Paepe A, Speleman F, Vandesompele J. Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons. BMC Genomics 2004, 5:11. 10.1186/1471-2164-5-11, 365025, 15018647.
11. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007, 46:936-949. 10.1002/gcc.20477, 17647283.
12. Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, Nair P, Brothman AR, Stallings RL. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005, 44:305-319. 10.1002/gcc.20243, 16075461.
13. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008, 27:441-449. 10.1038/sj.onc.1210661, 17637744.
14. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2007, 2:e255. 10.1371/journal.pone.0000255, 1797488, 17327916.
15. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005, 65:6071-6079. 10.1158/0008-5472.CAN-05-0465, 16024607.
16. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007, 81:114-126. 10.1086/518809, 1950910, 17564968.
17. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009, 15:120-128. 10.1016/j.molmed.2009.01.005, 19246245.
18. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009, 27:298-303. 10.1200/JCO.2008.16.6876, 2650389, 19047290.
19. CNAG-copy number analyzer for Genechip, Cancer Genomics Project, Tokyo University. , http://www.genome.umin.jp
20. Frostad B, Martinsson T, Tani E, Falkmer U, Darnfors C, Skoog L, Kogner P. The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. Cancer 1999, 87:60-68. 10.1002/(SICI)1097-0142(19990425)87:2<60::AID-CNCR4>3.0.CO;2-9, 10227595.
21. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983, 71:741-747.
22. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
23. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148. 10.1038/nature03546, 15793561.
24. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790. 10.1056/NEJMoa051113, 15858187.
25. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397. 10.1016/j.ccr.2005.03.023, 15837627.
26. Robinson WP. Mechanisms leading to uniparental disomy and their clinical consequences. Bioessays 2000, 22:452-459. 10.1002/(SICI)1521-1878(200005)22:5<452::AID-BIES7>3.0.CO;2-K, 10797485.
27. Van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Salwen H, Laureys G, Manoel N, De Paepe A, Speleman F. Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes Cancer 2001, 32:126-135. 10.1002/gcc.1174, 11550280.
28. Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2007, 172:127-138. 10.1016/j.cancergencyto.2006.08.012, 17213021.
29. Cohen N, Betts DR, Rechavi G, Amariglio N, Trakhtenbrot L. Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-N-SH neuroblastoma cell line. Cancer Genet Cytogenet 2003, 143:80-84. 10.1016/S0165-4608(02)00835-X, 12742159.